Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C

@article{Scott2018LedipasvirSofosbuvirAR,
  title={Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C},
  author={Lesley J. Scott},
  journal={Drugs},
  year={2018},
  volume={78},
  pages={245-256}
}
Oral once-daily, fixed-dose, ledipasvir/sofosbuvir (Harvoni®) [± ribavirin] is approved in several countries for the treatment of chronic hepatitis C (CHC) in adults and adolescents aged 12 to < 18 years, with direct-acting antiviral (DAA) regimens resulting in a paradigm shift in the treatment of the disease. In the clinical trial and/or clinical practice setting, ledipasvir/sofosbuvir (± ribavirin) was associated with high sustained virological response rates 12 weeks post-treatment (SVR12… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 61 REFERENCES

The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.

  • Liver international : official journal of the International Association for the Study of the Liver
  • 2016
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Ledipasvir/sofosbuvir regimens for the retreatment of patients who failed sofosbuvir-based regimens [abstract no. O-011

E Lawitz, P Pockros, JC Yang
  • Hepatol Int. 2016;10(Suppl 1):S9
  • 2016
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

  • The New England journal of medicine
  • 2014
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL